Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low an...

Full description

Bibliographic Details
Main Authors: Koefoed, K., Steinaa, Lucilla, Soderberg, J.N., Kjaer, I., Jacobsen, H.J., Meijer, P.-J., Haurum, J.S., Jensen, A., Kragh, M., Andersen, P.S., Pedersen, M.W.
Format: Journal Article
Language:Inglés
Published: Informa UK Limited 2011
Subjects:
Online Access:https://hdl.handle.net/10568/35344

Similar Items: Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor